Incyte announced initiation of phase 3 RUXCOVID study evaluating Ruxolitinib (Jakafi) as treatment for COVID-19 patients
On Apr. 17, 2020, Incyte announced the initiation of RUXCOVID, a global, randomized, double-blind, placebo-controlled phase 3 clinical…